Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT01741727 (Clinical Trial / ABT-414)

Study Title
A Study of ABT-414 in Subjects With Solid Tumors (NCT01741727)

Trial Description
A study of ABT-414 in subjects with solid tumors.

This trial is sponsored by AbbVie.

Study Data

  • Condition: Squamous Cell Tumors
  • Interventions
    • Drugs used in this trial:
      • ABT-414
  • Phase: I
  • Enrollment: 57
  • Start: October 2012
  • Completion: November 2015
  • Last verified: February 2016

Study Schematic

Screen Shot 2016-07-19 at 4.46.42 PM

Return to drug map


Last Editorial review:  July 6, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

 

Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar